Xie X(#)(1), Liu Y(#)(1), Liu J(#)(2)(3), Zhang X(1), Zou J(1), Fontes-Garfias CR(1), Xia H(1), Swanson KA(4), Cutler M(4), Cooper D(4), Menachery VD(2)(3), Weaver SC(2)(3), Dormitzer PR(5), Shi PY(6)(7)(8)(9)(10). Author information:
(1)Department of Biochemistry and Molecular Biology, University of Texas Medical
Branch, Galveston, TX, USA.
(2)Departments of Microbiology and Immunology, University of Texas Medical
Branch, Galveston, TX, USA.
(3)Institute for Human Infection and Immunity, University of Texas Medical
Branch, Galveston, TX, USA.
(4)Pfizer, Pearl River, NY, USA.
(5)Pfizer, Pearl River, NY, USA. [Email]
(6)Department of Biochemistry and Molecular Biology, University of Texas Medical
Branch, Galveston, TX, USA. [Email]
(7)Institute for Human Infection and Immunity, University of Texas Medical
Branch, Galveston, TX, USA. [Email]
(8)Institute for Translational Sciences, University of Texas Medical Branch,
Galveston, TX, USA. [Email]
(9)Sealy Institute for Vaccine Sciences, University of Texas Medical Branch,
Galveston, TX, USA. [Email]
(10)Sealy Center for Structural Biology & Molecular Biophysics, University of
Texas Medical Branch, Galveston, TX, USA. [Email]
(#)Contributed equally
